U.S. health officials have advised patients to pause the Ixchiq vaccine after reports of serious adverse events. Investigations are ongoing as the FDA reassesses its safety for older adults.
American travelers aged 60 and older are advised against the chikungunya vaccine amid concerns over potential side effects. Investigations are underway following reports of serious health issues post-vaccination.
